NanoCarrier Co., Ltd. (JP:4571)
:4571
Want to see JP:4571 full AI Analyst Report?
Top Page
NanoCarrier Co., Ltd.
(4571)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥98.00
▼(-26.87% Downside)
Action:Reiterated
Date:05/17/26
The score is primarily weighed down by sustained heavy losses and ongoing cash burn, even with improving revenue and strong gross margins. Technicals are bearish with the price below major moving averages and negative MACD, though oversold indicators modestly temper the downside view. Valuation is difficult to support with negative earnings and no dividend yield data.
Positive Factors
Proprietary DDS platform
NanoCarrier’s micellar nanoparticle DDS platform is a durable competitive asset: it creates technical barrier to entry, supports multiple partnered programs, and underpins recurring licensing, milestone and royalty economics that can scale without large incremental fixed costs.
Negative Factors
Persistent negative operating cash flow
Consistent negative operating and free cash flow means the core operations do not fund themselves, creating ongoing reliance on external financing. Over 2-6 months this raises dilution and refinancing risk, constraining strategic flexibility and the ability to scale programs independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary DDS platform
NanoCarrier’s micellar nanoparticle DDS platform is a durable competitive asset: it creates technical barrier to entry, supports multiple partnered programs, and underpins recurring licensing, milestone and royalty economics that can scale without large incremental fixed costs.
Read all positive factors
NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥8.32B
Dividend YieldN/A
Average Volume (3M)2.35M
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth60.80%
EPS Growth-8.89%
CountryJP
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-12.48
Shares Outstanding83,221,756
10 Day Avg. Volume484,410
30 Day Avg. Volume2,345,523
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NanoCarrier Co., Ltd. Business Overview & Revenue Model
Company Description
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological...
How the Company Makes Money
NanoCarrier’s earnings are primarily tied to monetizing its drug delivery technology and associated drug candidates through (1) collaboration/licensing arrangements and (2) development-related consideration tied to partnered programs. In practice,...
NanoCarrier Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.22M | 174.50M | 108.52M | 135.51M | 202.19M | 264.03M |
| Gross Profit | 84.46M | 153.29M | 78.17M | 110.96M | 159.60M | 220.88M |
| EBITDA | -877.21M | -892.12M | -832.57M | -776.41M | -1.30B | -1.87B |
| Net Income | -880.20M | -943.88M | -835.38M | -780.00M | -1.31B | -1.88B |
Balance Sheet | ||||||
| Total Assets | 3.93B | 5.91B | 4.00B | 5.07B | 5.78B | 7.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.40B | 4.91B | 3.51B | 4.28B | 4.44B | 5.95B |
| Total Debt | 540.24M | 1.60B | 540.24M | 1.11B | 1.11B | 1.15B |
| Total Liabilities | 1.28B | 2.34B | 1.26B | 1.65B | 1.53B | 1.57B |
| Stockholders Equity | 2.66B | 3.57B | 2.74B | 3.42B | 4.25B | 5.57B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 0.00 | -585.08M | -1.09B | -1.76B |
| Operating Cash Flow | 0.00 | -816.67M | -401.62M | -585.08M | -1.09B | -1.75B |
| Investing Cash Flow | 0.00 | 2.26B | 587.53M | 793.01M | 1.21B | -244.13M |
| Financing Cash Flow | 0.00 | 2.22B | -568.77M | 3.73M | 32.20M | 1.15B |
NanoCarrier Co., Ltd. Technical Analysis
Negative
134.00
Price Trends
128.20
Negative
143.58
Negative
147.20
Negative
Market Momentum
-8.66
Negative
32.56
Neutral
68.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 134 is above the 20-day moving average (MA) of 108.30, above the 50-day MA of 128.20, and below the 200-day MA of 147.20, indicating a bearish trend. The MACD of -8.66 indicates Negative momentum. The RSI at 32.56 is Neutral, neither overbought nor oversold. The STOCH value of 68.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.
NanoCarrier Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥19.14B | -3.75 | -184.71% | ― | 29.94% | 86.03% | |
47 Neutral | ¥75.85B | -49.50 | ― | ― | 0.80% | 32.87% | |
45 Neutral | ¥8.32B | -8.41 | -26.70% | ― | 60.80% | -8.89% | |
45 Neutral | ¥8.37B | -11.51 | -63.25% | ― | 7.80% | 12.92% | |
42 Neutral | ¥12.33B | -17.95 | ― | ― | -66.35% | -409.99% | |
40 Underperform | ¥5.23B | -5.19 | ― | ― | -23.82% | 14.80% |
* Healthcare Sector Average
JP:4571
NanoCarrier Co., Ltd.
100.00
-50.00
-33.33%
JP:4563
AnGes
48.00
-17.00
-26.15%
JP:4564
OncoTherapy Science
21.00
-2.00
-8.70%
JP:4583
Chiome Bioscience Inc.
67.00
-84.00
-55.63%
JP:4588
Oncolys BioPharma, Inc.
2,591.00
1,973.00
319.26%
JP:4888
STELLA PHARMA CORPORATION
352.00
-45.00
-11.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.